Previous close | 65.27 |
Open | 65.50 |
Bid | 65.37 x 800 |
Ask | 65.50 x 800 |
Day's range | 64.64 - 66.35 |
52-week range | 64.63 - 87.87 |
Volume | |
Avg. volume | 7,428,992 |
Market cap | 81.577B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 14.54 |
EPS (TTM) | 4.50 |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | 3.08 (4.72%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | 83.88 |
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
Q1 2024 Gilead Sciences Inc Earnings Call
FOSTER CITY, Calif., April 26, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy of